Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Vaccine Development & Protection Study Service
Navigate complex vaccine development with confidence and precision. Accelerate Your Drug Discovery Process! Are you currently facing long drug development cycles or complex clinical trials? Our NHP Vaccine Challenge & Protection Studies Service helps you streamline clinical trial processes and accelerate drug discovery through a deep understanding of correlates of protection and highly controlled, reproducible animal models. We provide a clear pathway from concept to preclinical data, ensuring your project advances with speed and scientific rigor.
Introduction of NHP Vaccine Development & Protection Studies Service
What Our Service Is
The Creative Biolabs NHP Vaccine Challenge & Protection Studies Service provides a comprehensive platform for the preclinical evaluation of vaccine candidates in NHPs. Our service is designed to generate robust, reproducible data on vaccine efficacy and mechanism of action. We provide end-to-end support for viral challenge studies, from animal model selection and experimental design to sophisticated data analysis. Our services are used to:
- Evaluate the protective efficacy of novel vaccine candidates against infectious agents.
- Determine the correlates of protection to inform future vaccine design.
- Provide robust safety and efficacy data for regulatory submissions.
Why Choose Us?
Developing an effective vaccine is a long and resource-intensive journey, often complicated by the need for reliable preclinical models that accurately predict human responses. The challenge of a complex clinical trial environment and the difficulty in assessing true efficacy in a preclinical setting can lead to significant delays and costs. Creative Biolabs solves this by providing a highly controlled and scientifically rigorous NHP platform. Our services accelerate the drug discovery process by providing clear, actionable data that directly addresses critical questions about your vaccine candidate's performance.
Fig.1 A DNA-based vaccine platform formulation induces an immune response in non-human primates and facilitates viral control in vivo.1
Key Benefits of Our Service
Our service is built on a foundation of scientific excellence and a commitment to precision. We leverage our extensive expertise to provide unique advantages that set your project up for success.
- Responsiveness: We are dedicated to providing rapid response times from initial inquiry to final data delivery, ensuring your project stays on track.
- Comprehensive NHP Resources: Our access to a diverse and well-characterized NHP cohort allows for study design flexibility and accelerated timelines. We ensure the use of appropriate species and strains for each specific research need.
- Customization: Every project is unique. Our team collaborates with you to design a study protocol that is precisely tailored to your research objectives, from selecting the pathogen strain to defining the endpoints.
- In-Depth Reporting: Our reports go beyond raw data. We provide detailed analyses, including insights into viral dynamics and immune responses, helping you understand how and why your vaccine is effective.
How Creative Biolabs' Service Can Assist Your Project?
Our NHP Vaccine Challenge & Protection Studies Service provides a clear, scientifically grounded pathway to proving the efficacy of your vaccine candidate. We go beyond simple challenge outcomes to provide a deep understanding of the mechanisms of protection, such as how your vaccine may decrease the rate of cell infection or increase the clearance of infected cells.
01
Required Starting Materials
02
Protocol Design and Approval
03
Animal Acclimation and Baseline Sampling
04
Immunization and Prime/Boost Schedule
05
Pathogen Challenge
06
Post-Challenge Monitoring and Data Collection
Key Deliverables
Upon completion of your project, you will receive a comprehensive data package tailored to your needs, including:
- Final Study Report
- Raw and analyzed data files
- Detailed pathology and histology reports
- Bio-specimen inventory and management reports
- Model annotations and statistical analyses
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: Why are NHP models the ideal choice for my vaccine study?
A: NHP models are a gold standard for preclinical vaccine studies because of their high genetic and immunological similarity to humans. This close relationship allows for more accurate and predictive results, making NHP data a critical component for advancing a vaccine candidate toward clinical trials.
Q: What kind of pathogens can you work with in your challenge studies?
A: We have extensive experience with a wide range of infectious agents, including respiratory, viral, and bacterial pathogens. Our facilities are equipped with the necessary biosafety protocols to handle various challenge agents safely and effectively. We encourage you to discuss your specific pathogen needs with our team.
Q: How does your service help me understand the "mechanism of protection"?
A: Our service is designed to go beyond a simple pass/fail result. We collect extensive data on viral load kinetics, antibody titers, and cellular immune responses, which allows us to identify the key biological mechanisms driving protection. This helps you understand not only if your vaccine works, but how it works, informing your next steps.
Q: How do your NHP studies compare to using mouse models?
A: While mouse models are a valuable tool for initial screening, NHP models provide a much more robust and translatable platform for late-stage preclinical evaluation. They offer a more accurate representation of the human immune system and disease progression, making them essential for a strong regulatory submission.
Contact Us
The Creative Biolabs NHP Vaccine Challenge & Protection Studies Service provides the scientific rigor, data-driven insights, and ethical standards required to accelerate your vaccine development program. From comprehensive study design to in-depth analysis of protective mechanisms, our team is equipped to be your trusted partner. Contact our team today for a detailed discussion about your project's unique requirements. Our specialists are ready to provide expert guidance and a customized proposal.
Reference
- Sood, Subeena, et al. "Intramuscular DNA vaccine provides protection in non-human primate and mouse models of SARS-CoV-2." Frontiers in Immunology 16 (2025). Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3389/fimmu.2025.1589584